National Cancer Institute (NCI)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).

3,257 total trials 326 currently recruiting 2051 completed early-phase tilt top decile by trial count

National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.

National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.

Top-decile sponsor footprint

National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

3,257 total, page 54 of 66

COMPLETED Phase 1

Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors

NCT00039390
COMPLETED Phase 2

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

NCT00036751
COMPLETED Phase 3

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00033332
COMPLETED Phase 2

Imatinib Mesylate in Treating Patients With Myelofibrosis

NCT00039416
COMPLETED Phase 2

Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00022659
COMPLETED Phase 1

Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

NCT00039117
COMPLETED Phase 2

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

NCT00039104
COMPLETED Phase 1

UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

NCT00039403
COMPLETED Phase 2

Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00039377
COMPLETED Phase 2

CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

NCT00033267
TERMINATED Phase 2

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00040768
TERMINATED Phase 1

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

NCT00039455
COMPLETED Phase 2

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

NCT00028002
COMPLETED Phase 1

Ketoconazole Plus Docetaxel to Treat Prostate Cancer

NCT00032825
COMPLETED

Cell Lines From High-Risk Breast Tissue

NCT00032201
COMPLETED

The New England Bladder Cancer Study

NCT00342875
TERMINATED

Genetic Analysis of Brain Tumors

NCT00031538
COMPLETED Phase 2

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

NCT00031694
COMPLETED Phase 2

Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix

NCT00031993
COMPLETED Phase 3

Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases

NCT00033254
COMPLETED Phase 1

UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors

NCT00036777
COMPLETED Phase 1

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

NCT00052208
COMPLETED Phase 1

Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children

NCT00032669
COMPLETED Phase 1

CC-5013 in Treating Patients With Recurrent Glioma

NCT00036894
COMPLETED Phase 2

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

NCT00033462
COMPLETED

Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C

NCT00040729
TERMINATED Phase 1

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

NCT00039091
TERMINATED Phase 2

Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer

NCT00009984
COMPLETED Phase 2

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

NCT00033358
COMPLETED Phase 2

Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer

NCT00024154
COMPLETED Phase 2

Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer

NCT00028834
COMPLETED Phase 2

BMS-247550 in Treating Patients With Stage IV Melanoma

NCT00036764
COMPLETED Phase 2

Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

NCT00026234
COMPLETED Phase 2

CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00028028
COMPLETED Phase 1

KRN5500 in Treating Patients With Solid Tumors

NCT00017238
COMPLETED Phase 2

BMS 247550 to Treat Kidney Cancer

NCT00030992
TERMINATED Phase 1

Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00033449
COMPLETED

A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen

NCT00341588
COMPLETED Phase 1

Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors

NCT00031928
COMPLETED Phase 1

2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors

NCT00028821
COMPLETED Phase 1

Karenitecin in Treating Patients With Recurrent Malignant Glioma

NCT00014521
COMPLETED Phase 2

Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer

NCT00032188
COMPLETED Phase 1

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

NCT00027898
COMPLETED Phase 2

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

NCT00032045
COMPLETED Phase 1

BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

NCT00057850
COMPLETED Phase 2

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

NCT00033371
COMPLETED Phase 1

Decitabine in Treating Patients With Advanced Solid Tumors

NCT00030615
COMPLETED Phase 1

PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

NCT00028587
COMPLETED Phase 1

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

NCT00031681
COMPLETED Phase 1

R(+)XK469 in Treating Patients With Advanced Neuroblastoma

NCT00028522
← Previous Page 54 of 66 Next →

Phase Distribution

PhaseTrial count
Phase 1 1199
Phase 2 1429
Phase 3 193

Therapeutic Areas

Advanced Malignant Solid Neoplasm 67
Refractory Malignant Solid Neoplasm 45
Metastatic Malignant Solid Neoplasm 38
Refractory Multiple Myeloma 35
Prostate Cancer 34
Refractory Lymphoma 33
Advanced Lymphoma 33
Acute Myeloid Leukemia 28
Unspecified Adult Solid Tumor, Protocol Specific 26
Breast Cancer 23

What is open in the National Cancer Institute (NCI) pipeline

326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).

Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).

Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.